A Phase I Study of Dasatinib with Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer by Humera Khurshid et al.
ORIGINAL RESEARCH ARTICLE
published: 31 May 2012
doi: 10.3389/fonc.2012.00056
A phase I study of dasatinib with concurrent
chemoradiation for stage III non-small cell lung cancer
Humera Khurshid ,Thomas Dipetrillo,Thomas Ng, Kalyan Mantripragada, Ariel Birnbaum, David Berz,
Kathy Radie-Keane, Kimberly Perez, Maria Constantinou, Denise Luppe, Andrew Schumacher ,
Kara Leonard and Howard Safran*
The Brown University Oncology Group, Providence, RI, USA
Edited by:
Minesh P. Mehta, Northwestern
University, USA
Reviewed by:
Daniel Grant Petereit, Rapid City
Regional Hospital, USA
Skye Hung-Chun Cheng, Koo
Foundation SunYat-Sen Cancer
Center, Taiwan
*Correspondence:
Howard Safran, Department of
Medicine, Rhode Island Hospital, 593
Eddy Street, Providence, RI 02903,
USA.
e-mail: hsafran@lifespan.org
Objectives: Src family kinases (SFKs) are expressed in non-small cell lung cancer (NSCLC)
and may be involved in tumor growth and metastases. Inhibition of SFK may also enhance
radiation.The purpose of this study was to evaluate if a maximum dose of 100mg of dasa-
tinib could be safely administered with concurrent chemoradiation and then continued as
maintenance for patients with newly diagnosed stage III NSCLC. Methods: Patients with
stage III locally advanced NSCLC received paclitaxel, 50mg/m2/week, with carboplatin
area under the curve (AUC)= 2, weekly for 7weeks, and concurrent radiotherapy, 64.8Gy.
Three dose levels of dasatinib 50, 70, and 100mg/day were planned. Results: 11 patients
with locally advanced NSCLC were entered. At the 70mg dose level 1 patient had grade 5
pneumonitis not responsive to therapy, and one patient had reversible grade 3 pneumonitis
and grade 3 pericardial effusion. Due to these toxicities the Brown University Oncology
Group Data Safety Monitoring Board terminated the study. Conclusion: Dasatinib could
not be safely combined with concurrent chemoradiation for stage 3 lung cancer due to
pneumonitis.
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INTRODUCTION
Concurrent chemoradiation is the standard treatment for locally
advanced stage III non-small cell lung cancer (NSCLC). How-
ever, the majority of patients will develop locoregional and dis-
tant metastases. RTOG 0617, a randomized phase III study of
standard-dose (60Gy) versus high dose (74Gy) radiotherapy with
concurrent and consolidation carboplatin/paclitaxel ± cetuximab
for patientswith stage IIIA/IIIBNSCLC showedno survival beneﬁt
for high dose radiation (Bradley et al., 2011).
Additional chemotherapy either before or after chemoradia-
tion also has not improved survival. The Hoosier Oncology Group
(HOG) phase III trial demonstrated no improvement in outcome
with the addition of three cycles of docetaxel 75mg/m2 after deﬁn-
itive chemoradiotherapy as compared to chemoradiation alone
(Hanna et al., 2008). The control group had a progression free
survival of 12.9months compared to 12months for the docetaxel
arm. Median overall survival was 24.1months for the observa-
tion arm and 21.5months for the docetaxel arm. CALGB 39801
demonstrated no improvement with induction chemotherapy
prior to chemoradiation as compared to chemoradiation alone
(Vokes et al., 2007). Two year overall survivals were 29 and 31%,
respectively. The addition of the EGFR small molecule tyrosine
kinase inhibitor geﬁtinib after chemoradiotherapy and consolida-
tion chemotherapy also failed to improve progression free survival
or overall survival (Kelly et al., 2008).
An agent that could block the growth and prevent the devel-
opment of micrometastases after locoregional therapy would have
substantial importance. The Src family kinases (SFKs) are integral
tomany signaling pathways regulating cellular functions including
proliferation, migration, and cellular survival (Kim et al., 2009).
Activated SFKs are commonly expressed in NSCLC (Masaki et al.,
2003; Zhang et al., 2007). Dasatinib is a potent inhibitor of SFKs
(Haura et al., 2010; Johnson et al., 2010). Clinical studies of single
agent dasatinib and the combination of dasatinib and erlotinib
have demonstrated modest activity in NSCLC (Haura et al., 2010;
Johnson et al., 2010). Inhibition of Src also enhances the sensitiv-
ity to radiation in NSCLC (Dittmann et al., 2009; Purnell et al.,
2009).
The Brown University Oncology Group initiated a phase I
study to determine whether dasatinib, up to a dose of 100mg/day
couldbe safely administeredwith concurrent chemoradiation.The
original protocol was designed to ﬁrst evaluate dasatinib with
chemoradiation for patients with unresectable NSCLC. If safety
was established in this group of patients, the protocol planned
for dasatinib to be investigated with neoadjuvant chemoradiation
to 50.4Gy followed by surgical resection in patients with poten-
tially resectable stage IIIA disease. Since approximately one-third
of patients with stage III NSCLC have grade 3/4 non-hematologic
toxicitieswith standard chemoradiation, the protocol alloweddose
escalation to continue until three or more of six patients had
dose limiting toxicities (DLT) at a given dose level. However,
because of severe pneumonitis in two patients with inoperable
lung cancer at the second dose level, this protocol was termi-
nated by the Brown University Oncology Group Data Safety
Monitoring Committee. This report describes protocol treatment
and toxicity.
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MATERIALS AND METHODS
PATIENTS
Patients with pathologically proven stage III NSCLC were eligi-
ble excluding patients with contralateral hilar lymphadenopathy.
Patients with supraclavicular lymph node involvement were only
eligible if they had an upper lobe primary tumor on the ipsi-
lateral side of the supraclavicular lymph node. Patients could
not have had prior chemotherapy or radiation for lung cancer.
No prior radiation for any other malignancy within the radia-
tion ﬁeld was permissible. Patents with a pleural or pericardial
effusion were excluded. Required diagnostic evaluation included
history and physical examination, PET scan and CT or MRI of
the brain. Mediastinoscopies were highly recommended. Patients
must be at least 3 weeks from prior thoracotomy (if performed),
ECOG performance status 0–1, and age>18. Required laboratory
parameters included absolute neutrophil count (ANC) >1,500
cells/ul, platelets >100,000 cells/ul, hemoglobin >9.0 g/dl, crea-
tinine<1.5× upper limit of normal (ULN), total bilirubin<2.0×
ULN, aspartate transaminase (AST), and alanine transaminase
(ALT) <2.5× the ULN, serum Na, K+, Mg2+, phosphate, and
Ca2+≥ lower limit of normal (LLN). Patients could not have a
severe active comorbidity.
CHEMOTHERAPY
Patients received paclitaxel, 50mg/m2/week and carboplatin, area
under the curve (AUC)= 2, weekly for 7weeks with concur-
rent radiation. Prior to the ﬁrst dosage of paclitaxel, patients
were premedicated with dexamethasone 20mg orally the night
before paclitaxel administration. Dexamethasone was adminis-
tered either intravenously 30min prior to paclitaxel adminis-
tration or orally 1–3 h prior to paclitaxel administration. Prior
to the ﬁrst dosage of paclitaxel, patients were premedicated
with diphenhydramine, 50mg intravenously, and ranitidine (or
other H2 blocker), 50mg intravenously. If no allergic reactions
occur, then subsequent dosages of dexamethasone, diphenhy-
dramine, and H2 blockers could be reduced at the investigator’s
discretion.
DASATINIB
Dasatinib was administered orally on a daily basis throughout
the 7weeks of chemoradiation. Patients were treated with dasa-
tinib according to a dose escalation scheme, with patients enrolled
in cohorts of 3–6 at each dose level. Three dose levels 50, 70,
and 100mg/day were planned. Beginning 28 days after comple-
tion of radiation, all patients would have dasatinib increased to
100mg/day and continued for 2 years or until disease progression
or unacceptable toxicity.
RADIOTHERAPY
Radiation therapy was initiated with the ﬁrst day of chemother-
apy. 3D conformal treatment was delivered. The total dose to the
involved areas for patients with unresectable NSCLC was 64.8Gy
in 35 fractions over 7weeks. This was administered at 1.8 Gy
daily, 5 days a week, for total of 25 fractions (45Gy) to the pri-
mary and mediastinum, followed by a boost to the primary and
involved nodes to 1.8Gy daily in 11 fractions (19.8Gy). A volu-
metric treatment planning CT study was required to deﬁne gross
tumor volumes (GTV), and planning target volume (PTV). Each
patient was positioned in an individualized immobilization device
in the treatment position on a ﬂat table. Alpha cradle or approved
alternate immobilization system was required.
Contiguous CT slices, 3–5mm thickness of the regions har-
boring gross tumor and grossly enlarged nodes and 8–10mm
thickness of the remaining regions, were obtained starting from
the level of the cricoid cartilage and extending inferiorly through
the liver. The GTV, CTV, and PTV and normal organs were out-
lined on all appropriate CT slices and displayed using beam’s eye
view. A measurement scale for the CT image was included.
Normal tissues contoured included both lungs, skin, heart,
spinal cord, esophagus, and liver. Dose constraints were deﬁned
such that the percent volumeof bilateral lung receiving 5Gy (V5Gy)
was limited to 65% and the volume receiving 20Gy (V20Gy) was
limited to 35%. The maximum dose to the heart was limited to
65Gy or less; the volume of heart receiving 40Gy was limited to
80% or less. The maximum dose to the esophagus was limited to
72Gy or less and the mean dose to the esophagus was limited to
34Gy or less.
RESPONSE
Response was evaluated using Response Evaluation Criteria in
Solid Tumors (RECIST) criteria.
STATISTICAL DESIGN
The frequency of patients experiencing an acute DLT from the
combination of dasatinib and chemoradiation was used for the
determination of the maximum tolerated dose (MTD). The deﬁ-
nition of DLT included acute grade 3 or grade 4 non-hematologic
toxicity (excluding alopecia), grade 4 neutropenia or thrombo-
cytopenia or any grade 5 toxicity related to treatment. For each
arm, three to six patients were to be accrued. After it was deter-
mined that no more than three of six patients had DLTs when
observed for at least 28 days after completion of radiation, the
dose level was considered acceptable and the next dose level
could be evaluated. Survival was calculated from the date of
study entry.
The institutional review boards of all participating hospitals
approved the study. All patients gave written informed consent
according to federal and institutional guidelines.
Table 1 | Patient characteristics.
Number of patients enrolled 11
Median age in years (range) 63 (40–84)
Male:Female 8:03
CELLTYPE
Adenocarcinoma 5
Squamous cell carcinoma 5
Non-small cell undetermined 1
ECOG PERFORMANCE STATUS
0 2
1 9
STAGE
III A 6
III B 5
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RESULTS
PATIENT CHARACTERISTICS
Eleven patients with unresectable lung cancer were enrolled in
this study between March 2009 and November 2010 and their
characteristics are listed in Table 1. The median age was 63. Six
patients had stage IIIA disease and ﬁve patients had stage IIIB dis-
ease. Nine patients had a performance status of 1 and two had a
performance status of 0.
TOXICITY
Six patients were entered at the dasatinib dose level of 50mg/day.
Of these six patients, one withdrew consent and was not evalu-
able for toxicity. Of the remaining ﬁve patients, one had grade 3
esophagitis. Since four of ﬁve patients in this cohort successfully
completed treatment, the protocol deﬁned MTD of three or more
of six patients developing DLT would not have been reached at
the 50mg dose level. Therefore accrual to dose level 2, dasatinib
70mg/day with chemoradiation, was initiated.
Five patients were entered at dose level 2. Two of ﬁve patients
developed pulmonary toxicity. One patient presented to the hospi-
tal 35 days after the last radiation dose with grade 3 pneumonitis
and grade 3 pericardial effusion. This patient was immediately
treated with prednisone with improvement of his symptoms and
subsequent resolution. The V5Gy and V20Gy in this patient were 62
and 33%, respectively and the volume of heart receiving 45Gy was
15%.These dose volumeparameters arewellwithin the constraints
for lung and heart dose commonly used in cooperative group pro-
tocols. A second patient developed severe dyspnea 25 days after the
last treatment with radiation. He had no prior history of lung dis-
ease, however his pretreatment DLCO was 52% of predicted prior
to treatment. The V5Gy and V20Gy from his radiation treatment
FIGURE 1 | Pneumonitis with pulmonary parenchymal abnormalities in
a patient with stage IIIA NSCLC treated with dasatinib and concurrent
chemoradiation.
were 40 and 25%, respectively. A CT scan of the chest done 10 days
before the visit showed decrease in size of the lung mass from
3.1 cm× 3.2 cm to 1.5 cm× 1.8 cm and decrease in size of medi-
astinal lymph node and a faint diffuse reticulonodular pattern in
the lungs. Repeat CT chest on admission with showed extensive
bilateral predominantly basilar diffuse interstitial disease as shown
in Figure 1 below.
Bronchoscopy was performed. All bacteriologic, viral, and fun-
gal cultures were negative and respiratory viral panel was negative.
He was treated with broad spectrum antibiotics, corticosteroids,
and diuretics. An echocardiogram showed right ventricular sys-
tolic pressure (RVSP) of 71mm Hg, indicating moderate pul-
monary hypertension. The patient’s respiratory status continued
toworsen and the patient expired.Acute toxicities of all 10 patients
assessable for toxicity are listed in Table 2. Multiple toxicities in a
single patient are scored as separate events.
Table 2 |Toxicity*.
Number of patients (n=10)
Grade 2 Grade 3 Grade 4
NON-HEMATOLOGICAL
1. Gastrointestinal
Nausea 1 1 0
Vomiting 1 0 0
Diarrhea 0 1 0
Dehydration 2 1 0
Heartburn 1 0 0
Esophagitis 2 4 0
Dysphagia 3 1 0
2. Constitutional
Fatigue 2 0 0
Anorexia 1 0 0
Weight loss 1 0 0
3. Cardiac
Chest pain 0 0 1
Troponin elevation 0 0 1
Cardiac ischemia 0 1 0
Pericardial effusion 0 1 0
Hypotension 0 1 0
Arrhythmia 1 0 0
4. Pulmonary
Pneumonitis 0 0 1
Dyspnea 0 1 0
Pleural effusion 0 3 0
5. Infections
Infection with normal ANC 0 1 0
6. Allergies
Carboplatin 1 0 0
HEMATOLOGICAL
Neutropenia 0 2 0
Anemia 0 2 0
Thrombocytopenia 0 0 0
*Multiple toxicities in the same patient are scored as separate events.
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Of the 10 assessable patients accrued, two had a partial
response. The median survival is 18months. Five patients remain
alive at 18, 21, 27, 27, and 32 month follow-up.
DISCUSSION
The Brown University Oncology Group sought to investigate the
addition of a Src inhibitor to chemoradiation for stage 3 NSCLC.
Exposure to ionizing radiation can activate the epidermal growth
factor receptor (Schmidt-Ullrich et al., 1997). Src kinase activation
plays a crucial role during this process. Radiation activated Src
kinase initiates EGFR internalization and nuclear transport (Khan
et al., 2006). Purnell et al. (2009) reported that Src was activated
in four of ﬁve lung cancer cell lines and the level corresponded
with the invasive potential. Submicromolar concentrations of the
Src inhibitor AZD0530 blocked Src and focal adhesion kinase,
resulting in signiﬁcant inhibition of cell migration and invasion.
Src inhibition gave a potent and sustained blockage of AKT and
enhanced sensitivity to radiation (Purnell et al., 2009).
Dasatinib has been evaluated in clinical studies in NSCLC.
Johnson et al. (2010) evaluated single agent dasatinib in patients
with advanced non-small-cell lung cancer. Thirty-four patients
were enrolled. The ﬁrst 22 patients received dasatinib 100mg twice
a day, however, because of poor tolerance (fatigue and pleural effu-
sion), the remaining 11 patients received dasatinib 100mg in the
morning and 50mg in the evening. Grade 3 dyspnea occurred in
15 patients (44%); 6 (18%) developed grade 3 pleural effusion.
Pleural effusions generally resolved with a short course of steroids,
diuretics, and temporary interruption with dasatinib. The over-
all disease control rate (partial responses plus stable disease) for
dasatinib was 43%. One patient had a partial response to therapy
and 11 patients (32%) had a metabolic response by PET scan. The
presence of a pleural effusion before dasatinib therapy predicted
the development of a clinically signiﬁcant effusion during therapy.
Haura et al. (2010) performed a phase I/II study of dasatinib
with erlotinib in 30 patients with NSCLC. The average duration
of treatment was 73 days. Two partial responses and one bone
response were observed and the disease control rate was 63%.
Six patients (18%) had grade 2 pleural effusions. Other toxicities
included diarrhea, anorexia, nausea, rash, hematologic toxicity,
and fatigue (Haura et al., 2010).
Concurrent chemoradiation can cause pulmonary toxicity. In
CALGB 39801 the incidence of grade 3 and grade 4 pneumonitis in
patients receiving chemoradiation (without induction chemother-
apy) was 3 and 1%, respectively (Vokes et al., 2007). The Brown
University sought to establish whether dasatinib could be safely
added to chemoradiation. To minimize patient risk, patients with
any pleural effusion were not eligible for this study. A maxi-
mum dose of 100mg/day was targeted based on a randomized
phase III study in patients with Philadelphia chromosome positive
hematologic malignancies (Shah et al., 2008). Compared with the
70mg twice-daily regimen, dasatinib 100mg once daily resulted
in signiﬁcantly lower rates of pleural effusion (all grades 7 ver-
sus 16%; p = 0.024) and grade 3–4 thrombocytopenia (22 versus
37%, p = 0.004) and fewer patients required dose interruption,
reduction, or discontinuation (Shah et al., 2008).
However, the 100mg target dose could not be achieved in
this phase I study. Fatal pneumonitis, complicated by pulmonary
hypertension in one patient, and a second patient with reversible
pneumonitis and pericardial effusion, developed at the 70mg dose
level. In the patient who developed grade 5 toxicity, in addition to
pleural effusion, the patient developed parenchymal pulmonary
abnormalities and pulmonary hypertension. There are four sepa-
rate case reports of pulmonary hypertension with dasatinib (Mat-
tei et al., 2009;Rasheed et al., 2009;Dumitrescu et al., 2011;Orlandi
et al., 2012). Parenchymal changes (ground glass or alveolar opac-
ities and septal thickening) with and without pleural effusion has
also been described (Bergeron et al., 2007). It is possible that the
pneumonitis observed in this study was due to chemoradiation
alone or that a safe low dose of dasatinib could possibly have been
detected. However, due to the severity of the toxicity, combined
with other case reports of pulmonary hypertension and its irre-
versible nature, the BrownUniversityOncologyGroupData Safety
Monitoring Committee recommended study closure.
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